Grifols, S.A. (NASDAQ:GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Nuria Pascual Thomas Glanzmann Let me now walk you through how we are meeting our other commitments. Q3 was another quarter of strong revenue growth, where we also delivered a 25.1% adjusted EBITDA margin, which is a significant improvement of 480 basis points compared to Q4 '22 margin. The revenue growth was primarily driven by biopharma and our flagship franchises, immunoglobulin and albumin, and we expect that moment ...

Victor Grifols Deu Okay. Thank you. We have now on the line Tom Jones from Berenberg. Hi, Tom. Alfredo Arroyo Nuria Pascual Nuria Pascual Victor Grifols Deu Thank you. And next question coming from Alvaro Lenze from Alantra Equities. Alvaro? Victor Grifols Deu Okay. We have a question from - coming from JoaquÃn GarcÃa-Quirós from JB Capital. Hi, JoaquÃn. Victor Grifols Deu Great. We have a couple of follow-up questions. First from - he was the first to be again nonetheless Tom, I think you have something el ...

Solid start to the year, while advancing on the turnaround plan backed by a new performance culture | --- | --- | --- | --- | --- | |-------|--------------------------------------------------------|-------------------------------------------------------------------------------|-------|------------------------------------------------------------------| | | Governance | Operational Improvement Plan | | Accelerating deleverage | | • | Formalized roles and responsibilities within SELT | • Deployed 80%+ of the E ...

Nuria Pascual Victor Grifols Deu Thank you. Thank you, Victor and thank you, Guilherme. Now is the turn for Berenberg, Tom Jones. Hi, Tom. We have lost Tom? Thomas Glanzmann Tom Jones Tom Jones Jaime Escribano Hello, Jaime. I'll take the first one. We are, let's say grams wise being sold for us compared to pre-to-'19. We are not yet there, but we are very close after our plasma recovery. Jaime Escribano First of all from the cash savings perspective, we expect it and we see those basis after a significant d ...

Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ◻ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ◻ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) O ...

Legal Disclaimer This presentation contains forward-looking information and statements about GRIFOLS based on current assumptions and forecast made by GRIFOLS management, including pro forma figures, estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally ident ...

Alfredo Arroyo Slide 16 shows the 2022 P&L with an accelerated growth and improved profitability. Revenues on -- Q4 revenues were up by 20.9% at constant currency versus prior year, reaching EUR1.7 billion. On a reported basis, this growth represented a 34.7% increase. Top line for the full year increased by EUR1 billion, reaching EUR6 billion, representing close to 23% increase versus prior year of 20 -- 12.4% growth at constant currency on the back of a strong organic growth of Biopharma, positive Biotest ...

2021 Investor and Analyst Day June 3, 2021 GRIFOLS جريفولز 基立福 2006-2021 2021 Disclaimer Investor & Analyst Day June 21 This document has been prepared by GRIFOLS, S.A. (GRIFOLS or the "Company") exclusively for use during the 2021 Investor and Analyst Day on June 3, 2021. Therefore it cannot be disclosed or made public by any person or entity with an aim other than the one expressed above, without the prior written consent of the Company. The Company does not assume any liability for the content of this do ...